Holen Sie sich die Stockscreener-App
0.7663
4.97%
0.0363
Handel nachbörslich:
.80
0.0337
+4.40%
Schlusskurs vom Vortag:
$0.73
Offen:
$0.77
24-Stunden-Volumen:
241.26K
Relative Volume:
0.81
Marktkapitalisierung:
$24.92M
Einnahmen:
$950.10K
Nettoeinkommen (Verlust:
$-16.69M
KGV:
-0.9233
EPS:
-0.83
Netto-Cashflow:
$-15.16M
1W Leistung:
-17.79%
1M Leistung:
-17.14%
6M Leistung:
-44.47%
1J Leistung:
-29.70%
1-Tages-Spanne:
$0.7317
$0.80
1-Wochen-Bereich:
$0.7228
$0.95
52-Wochen-Spanne:
$0.693
$1.80
Femasys Inc Stock (FEMY) Company Profile
Firmenname
Femasys Inc
Sektor
Telefon
770-500-3910
Adresse
3950 JOHNS CREEK COURT, SUWANEE
Vergleichen Sie FEMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.7663 | 23.74M | 950.10K | -16.69M | -15.16M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
482.35 | 171.42B | 9.15B | 2.63B | 1.99B | 7.17 |
|
BDX
Becton Dickinson Co
|
195.96 | 55.88B | 21.39B | 1.61B | 2.55B | 5.56 |
|
ALC
Alcon Inc
|
86.48 | 42.55B | 9.93B | 1.12B | 1.43B | 2.26 |
|
RMD
Resmed Inc
|
288.28 | 41.48B | 5.15B | 1.40B | 1.65B | 9.51 |
|
WST
West Pharmaceutical Services Inc
|
246.22 | 17.25B | 2.90B | 467.20M | 306.90M | 6.37 |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Optimistic Buy Rating for Femasys Driven by Strategic Initiatives and Product Innovations - TipRanks
Femasys Revenue Jumps 85 Percent in Q2 - AOL.com
HC Wainwright & Co. Lowers FEMY Price Target to $8.00, Maintains Buy Rating - AInvest
H.C. Wainwright Reiterates Buy Rating for Femasys with $8 Price Target - AInvest
Femasys:HC Wainwright Maintains Buy, PT Down to $8 from $12 - AInvest
Femasys earnings matched, revenue fell short of estimates By Investing.com - Investing.com Nigeria
Femasys earnings matched, revenue fell short of estimates - Investing.com India
Femasys Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Femasys reports Q2 EPS (16c) vs. (21c) last year - TipRanks
Is Femasys Inc. in a bullish channelTrend Confirmation Stock Picks - mustnews.co.kr
Options Data Show Bullish Bias in Femasys Inc.Portfolio Diversification Stock Ideas From Experts - beatles.ru
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates - MSN
Is Femasys Inc. a turnaround storyBig Picture ROI Planning - kangso.co.kr
Femasys Q2 2025 Financial Results: A Strategic Inflection Point for Women's Health Innovation - AInvest
Femasys 2025 Q2 Earnings Slight Earnings Improvement Amid Persistent Losses - AInvest
Femasys Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Femasys Announces Second Quarter Financial Results for 2025 - GlobeNewswire
Femasys Inc. (FEMY): Navigating Financial Challenges and Product Viability in a Competitive Women's Health Market - AInvest
Femasys Q2 Earnings Miss Estimates, Revenue Down 48.88% - AInvest
Femasys Q2 Revenue Surges 85%, Posts Narrower Net Loss and Gains European Approval for FemBloc. - AInvest
Femasys Revenue Jumps 85 Percent in Q2 - The Motley Fool
Femasys Inc reports results for the quarter ended June 30Earnings Summary - TradingView
FEMASYS INC SEC 10-Q Report - TradingView
Femasys Announces Q2 Financial Results, Regulatory Approvals, and Commercial Progress. - AInvest
Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion - GlobeNewswire
Femasys Inc. shares fall 4.54% intraday despite securing first European order for FemBloc. - AInvest
Femasys secures first European order for FemBloc - TipRanks
Femasys secures first European order for FemBloc, marking strategic milestone in global expansion - MarketScreener
Femasys Inc. Secures First European Order for Fembloc, Marking Strategic Milestone in Global Expansion - MarketScreener
Femasys Enters European Market with Major Spain Order - TipRanks
Femasys' Breakthrough in Non-Surgical Contraception: A Disruptive Force in a Fragmented Market - AInvest
Femasys receives first European commercial order for FemBloc contraceptive By Investing.com - Investing.com Nigeria
Femasys Secures First European Order for FemBloc Permanent Birth Control Solution - AInvest
Femasys receives first European commercial order for FemBloc contraceptive - Investing.com
Why Femasys Inc. stock attracts strong analyst attentionShort Term High Yield Stock Tips for Active Traders - beatles.ru
Femasys Inc expected to post a loss of 18 cents a shareEarnings Preview - TradingView
What are Femasys Inc. company’s key revenue driversRapidly growing investment returns - Jammu Links News
What analysts say about Femasys Inc. stockInvest confidently with professional market insights - Jammu Links News
Is Femasys Inc. a good long term investmentGet alerts on top growth stocks daily - Jammu Links News
How many analysts rate Femasys Inc. as a “Buy”Get exclusive market analysis for investors - Jammu Links News
What are the technical indicators suggesting about Femasys Inc.Sky-high return potential - Jammu Links News
How strong is Femasys Inc. company’s balance sheetAccess high-yield investment alerts now - Jammu Links News
Is Femasys Inc. a growth stock or a value stockOutstanding investment returns - Jammu Links News
What is the risk reward ratio of investing in Femasys Inc. stockTrack stocks with high upside potential easily - Jammu Links News
Is it the right time to buy Femasys Inc. stockInvest smarter with daily trading signals - Jammu Links News
What are analysts’ price targets for Femasys Inc. in the next 12 monthsDaily Trading Alerts For Every Investor - jammulinksnews.com
What catalysts could drive Femasys Inc. stock higher in 2025AI Powered Tracker To Watch Now - Jammu Links News
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):